Mirum Pharmaceuticals, Inc. MIRM
89.70
0.34
0.38%
as of 25 Sep
- Market cap
- $5.8B
- P/E
- 0.0×
Follow MIRM
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.00 | 9.54 | 7.61 | 7.87 | |
P/FCF ratio |
0.00 | 0.00 | 132.73 | 192.17 | |
P/Operating CF |
(167.66) | (23.77) | 653.56 | 93.55 | |
P/B ratio |
0.00 | 22.42 | 12.60 | 12.71 | |
Price to Tangible BV |
0.00 | 0.00 | 73.74 | 61.72 | |
EV/Sales |
12.51 | 9.41 | 7.47 | 7.73 | |
EV/EBITDA |
0.00 | 0.00 | 1,011.60 | 0.00 | |
EV/Operating CF |
(34.02) | (31.35) | 69.71 | 81.58 | |
EV/FCF |
(28.24) | (26.47) | 130.27 | 188.74 | |
Quick Ratio |
2.62 | 1.90 | 2.46 | 3.01 | |
Current Ratio |
2.86 | 2.09 | 2.67 | 3.31 | |
Net Debt/EBITDA |
(8.92) | 0.10 | (37.84) | (7.27) | |
Debt/Assets |
71.78% | 34.82% | 36.76% | 39.40% | |
Debt/Equity |
(71.97) | 1.28 | 0.98 | 1.06 | |
Asset Turnover |
0.70 | 0.72 | 0.69 | 0.65 | |
Operating CF/Net income |
0.66 | 0.29 | (1.06) | 13.66 | |
Capex/Depreciation |
(3.30) | (1.46) | (0.09) | (0.03) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
60.69% | 515.51% | 34.32% | 32.30% | |
Selling, General and Administrative Expense of Revenue |
46.23% | 60.25% | 49.77% | 46.55% | |
Intangible Assets out of Total Assets |
0.24 | 0.29 | 0.31 | 0.30 | |
Share Based Compensation of Revenue |
17.35% | 22.64% | 12.77% | 13.63% | |
Graham Net Nets |
(0.06) | (0.01) | 0.01 | 0.01 | |
Graham Number |
7.33 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.42%) | (14.72%) | (0.60%) | (1.16%) | |
Free Cash Flow Yield |
(3.69%) | (3.73%) | 0.75% | 0.52% | |
Revenue per Share |
2.78 | 2.72 | 2.97 | 2.63 | |
Operating CF per Share |
(0.70) | (3.89) | 0.12 | 0.78 | |
Capex per Share |
(0.39) | (0.18) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.09) | (4.07) | 0.11 | 0.78 | |
Cash per Share |
6.92 | 6.56 | 7.64 | 7.42 | |
Shareholders Equity per Share |
(0.16) | 4.12 | 6.27 | 5.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.16) | 4.12 | 6.27 | 5.77 | |
Free Cash Flow |
(69.27) | (239.43) | 5.47 | 39.49 | |
Working Capital |
413.52 | 296.61 | 343.89 | 370.22 | |
Capital Expenditures |
(25.02) | (10.66) | (0.60) | (0.19) | |
Net Current Asset Value |
(419.09) | (78.99) | 21.56 | 37.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.14 | 0.07 | 0.00 | 0.00 | |
Net Profit Margin |
(38.14%) | (494.21%) | (3.85%) | 2.18% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
126.10 | 114.48 | 100.81 | 87.83 | |
Average Payables |
20.54 | 35.52 | 12.12 | 10.86 | |
Average Inventory |
24.36 | 23.97 | 23.65 | 22.81 | |
Average Assets |
885.40 | 790.58 | 756.78 | 726.50 | |
Average Common Equity |
122.37 | 237.88 | 270.17 | 262.04 |
Columns are period end dates